Table 1.
Summary of patient characteristics at baseline.
| HIV/HCV-coinfected | HCV-mono | HIV-mono | |
|---|---|---|---|
| No. | 33 | 9 | 26 |
| Gender (male) | 25 (75.8%) | 7 (77.8%) | 16 (61.5%) |
| Age (years) | 51.5 (48.8; 53.1) | 63.5 (55.8; 71.2) | 51 (46; 53) |
| High alcohol intake | |||
| Previously (≥ 6 months) | 15 (45.5%) | 6 (66.7%) | 0 (0%) |
| Currently | 14 (42.4%) | 3 (33.3%) | 1 (3.8%) |
| IVDU | |||
| Previously (≥ 6 months) | 27 (81.8%) | 0 (0%) | 0 (0%) |
| Currently | 0 (0%) | 0 (0%) | 0 (0%) |
| Treatments | |||
| Previous IFNα therapy | 15 (45.5%) | 8 (88.9%) | – |
| DAAs regimens | |||
| Sofosbuvir + Ledipasvir | 14 (42.4%) | 3 (33%) | – |
| Sofosbuvir + Daclatasvir | 9 (27.3%) | 1 (11.1%) | – |
| Sofosbuvir + Daclatasvir + Simeprevir | 2 (6.1%) | 0 (0%) | – |
| Sofosbuvir + Simeprevir | 7 (21.2%) | 2 (22.2%) | – |
| Ombitasvir + Paritaprevir + Ritonavir + Dasabuvir | 1 (3%) | 3 (33%) | – |
| Antiretroviral therapy | |||
| NRTI+NNRTI-based | 5 (15.2%) | – | 16 (61.5%) |
| NRTI+II-based | 13 (39.4%) | – | 2 (7.7%) |
| NRTI+PI-based | 3 (9.1%) | – | 0 (0%) |
| PI+II+others-based | 4 (12.1%) | – | 0 (0%) |
| Others | 8 (24.2%) | – | 8 (30.8%) |
| HIV markers | |||
| Prior AIDS | 13 (39.4%) | – | 10 (38.5%) |
| Nadir CD4+ T-cells (cells/mm3) | 104.7 (70; 150) | – | 204 (99; 343) |
| Nadir CD4+ T-cells <200 cells/mm3 | 27 (90%) | – | 11 (44%) |
| CD4+ T-cells (cells/mm3) | 393 (234; 764) | – | 818 (685; 1036) |
| CD4+ T-cells <500 cells/mm3 | 19 (57.6%) | – | 0 (0%) |
| HIV-RNA >50 copies/mL | 0 (0%) | – | 0 (0%) |
| HCV markers | |||
| HCV genotype | |||
| 1 | 22 (68.8%) | 8 (88.9%) | – |
| 3 | 3 (9.4%) | 1 (11.1%) | – |
| 4 | 7 (21.9%) | 0 (0%) | – |
| Log10 HCV-RNA (IU/mL) | 6.3 (5.8; 6.7) | 6 (5.5; 6.2) | - |
| HCV-RNA ≥850.000 IU/mL | 24 (72.7%) | 5 (55.6%) | – |
| Liver disease | |||
| LSM (kPa) | 26.7 (19.2; 39.5) | 32.6 (22.3; 64) | – |
| HVPG (mmHg) | 14,5 (10; 17) | 17 (10; 20) | – |
Values are expressed as absolute number (percentage) and median (interquartile range).
HCV, hepatitis C virus; HIV, human immunodeficiency virus; IVDU, intravenous drug user; IFNα, interferon-alpha; DAAs, direct-acting antivirals; NRTI, nucleoside analogue HIV reverse transcriptase inhibitor; NNRTI, non-nucleoside analogue HIV reverse transcriptase inhibitor; PI, protease inhibitor; II, integrase inhibitor; AIDS, acquired immune deficiency syndrome; HCV-RNA, HCV plasma viral load; LSM, liver stiffness measures; kPa, kilopascals; HVPG, hepatic venous pressure gradient; mmHg, millimeter of mercury.